Evolution of Antipsychotic Therapy: A Mechanism-Based Evaluation

Journal of Clinical Psychiatry

Volumn 64, Issue 11, 2003, Pages 1379-1381

  Fleischhacker, W Wolfgang ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DIAZEPAM; DOCOSAHEXAENOIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; ESTROGEN; GAMMA ENDORPHIN; GLUTAMATE RECEPTOR AGONIST; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; HORMONE; ICOSAPENTAENOIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROPEPTIDE; OMEGA 3 FATTY ACID; RISPERIDONE; RITANSERIN; SEROTONIN 2 ANTAGONIST; UNINDEXED DRUG;

CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EVALUATION; FEMALE; HISTORY; HUMAN; MALE; MEDICAL SOCIETY; MONOTHERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT INDICATION;

EID: 0345413387     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Fleischhacker WW. New developments in the pharmacotherapy of schizophrenia. J Neural Transm Suppl 2003;64:105-117
2. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
3. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
4. Duinkerke SJ, Botter PA, Jansen AA, et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br J Psychiatry 1993;163:451-455
5. Den Boer JA, Vahlne JO, Post P, et al. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Hum Psychopharmacol 2000;15:179-189
6. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377
7. Heresco-Levy U, Javitt DC, Ermilow M, et al. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 1999;56:29-36
8. Coyle JT, Tsai G, Goff DC. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Target CNS Neurol Disord 2002;2:183-189
9. Evins AE, Amico E, Posever TA, et al. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 2002;56:19-23
10. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:463-493
11. Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001;49:243-251
12. Fenton WS, Dickerson F, Boronow J, et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001;158:2071-2074
13. Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002;159:1596-1598
14. Hafner H, Maurer K, Loffler W, et al. The epidemiology of early schizophrenia: influence of age and gender on onset and early course. Br J Psychiatry 1994;164 (suppl 23):29-38
15. Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential therapeutic implications: review. Arch Women Ment Health 2002;5:111-118
16. Kulkarni J, de Castella A, Smith D, et al. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr Res 1996;20:247-252
17. Kulkarni J, Riedel A, de Castella AR, et al. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia. Arch Women Ment Health 2002;5:99-104
18. Lindamer LA, Buse DC, Lohr JB, et al. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry 2001;49:47-51
19. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389